Somatostatin Receptor Expression in Colorectal Cancer
Author Information
Author(s): SAM Laws, AC Gough, AA Evans, MA Bains, JN Primrose
Primary Institution: University Departments of Surgery and Histopathology, Southampton General Hospital
Hypothesis
Somatostatin analogues may be useful novel agents in the systemic treatment of advanced colorectal cancer.
Conclusion
The study found that hSSTR2 is widely expressed in colonic tumors, while hSSTR5 expression is significantly reduced in metastatic tumors.
Supporting Evidence
- 87% of normal mucosae and malignant tissues expressed hSSTR2.
- hSSTR5 was expressed in 45% of mucosal and 46% of malignant samples.
- 75% of early-stage tumors expressed hSSTR5 compared to 31% of late-stage tumors.
- Only 11% of metastases expressed hSSTR5 compared with 56% of all primary tumors.
Takeaway
This study looked at how certain receptors related to somatostatin are found in colon cancer. They found one type, hSSTR2, is very common in tumors, while another type, hSSTR5, is less common in advanced cancer.
Methodology
The study used reverse transcription-polymerase chain reaction (RT-PCR) and in situ hybridization to analyze somatostatin receptor subtype expression in colorectal cancer specimens.
Limitations
The study's results should be interpreted with caution as mRNA levels do not necessarily indicate the presence of functionally coupled receptor protein.
Participant Demographics
The study included 32 colorectal cancer specimens, 31 mucosal specimens, and 9 metastatic specimens.
Statistical Information
P-Value
0.05
Statistical Significance
0.05>P>0.025
Want to read the original?
Access the complete publication on the publisher's website